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Intensive, high dose therapy with melphalan introduced by McElwain and 
colleagues in 1981 yields high remission rates but evidence on survival 
benefits has been inconclusive.  We have completed a prospective 
randomised Phase III trial of this approach.  Standard treatment consisted of 
ABCM for plateau induction with α -IFN maintenance.  Intensive treatment 
was a three-phase regimen of C-VAMP, high dose melphalan (with 
autologous bone marrow/peripheral blood stem cell support as appropriate) 
and α -IFN maintenance.  403 patients entered the trial from 82 centres.  The 
trial was conducted according to MRC Guidelines for Good Clinical Practice 
in Clinical Trials. 
The primary endpoints were survival and progression-free  survival.  
Secondary endpoints included response to treatment, quality of life, cause of 
death and toxicity of treatment.  Survival analysis was carried out with a 
median follow-up of 41 months for survivors.  There is improved survival in 
the Intensive treatment group (median survival 54.1 months compared with 
42.3 months in the Standard treatment group, p=0.047 log-rank test, p=0.034 
Wilcoxon test).  The presentation will present the results of overall survival 
and progression-free survival analyses and exploratory analyses of the impact 
of β 2-microglobulin levels on treatment effect and survival time. 
CT2 
GEMCITABINE/CARBOPLATIN (GC) VERSUS 
MITOMYCIN/IFOSFAMIDE/ CISPLATIN (MIP): A RANDOMISED 
COMPARISON IN PATIENTS WITH ADVANCED NON-SMALL 
CELL LUNG CANCER (NSCLC) 
*NH Gower
1, RM Rudd
2,  LE James
1, W Gregory
1, T Eisen
3, SM Lee
1, PG 
Harper
4, SG Spiro
1.
 1University College London, 
2St Bartholomew’s Hospital, 
London, 
3Royal Marsden Hospital, 
4Guy’s Hospital, London: On behalf of the 
London Lung Cancer Group. 
In this multicentre randomised trial we have compared a regimen commonly 
used in Europe, MIP, with the combination GC to test the hypothesis that, in 
patients with advanced NSCLC, GC would be at least as effective in terms of 
survival but associated with better quality of life (qol) and fewer hospital 
admissions.  
Both regimens were given in a 21-day cycle for up to 4 courses. GC 
comprised G 1,200mg/m
2 (IV days 1 and 8) and C AUC 5 (IV day 1). MIP 
comprised M 6mg/m
2, I 3G/m
2 and P 50mg/m
2 (all IV on day 1).  
Between February 1999 and August 2001 a total of 422 patients were 
randomised (GC - 212, MIP - 210). Patient characteristics: median age 62 
years, 70% male, 41% squamous cell, 47%/52% stage IIIb/IV, ECOG PS 
0:25%, 1:62%, 2:11%, 3:2%. By October 2001 88%/91% (GC/MIP) patients 
have completed chemotherapy. Of these 64% GC and 60% MIP received the 
intended 4 courses. More courses were delayed (11% vs 7%, p=0.009) with 
GC. Haematological toxicity was the main reason for delay in both arms 
(60% of delays GC, 50% MIP).  
GC required fewer in-patient admissions for administration (GC 14% of 
courses, MIP 89%) and was associated with less nausea, vomiting, alopecia 
(p<0.0001) and grade 3/4 constipation (p=0.02). Thrombocytopenia grade 3/4 
was greater with GC (GC 8% of courses, MIP 3%, p<0.0001), but this was 
not associated with increased hospital admission or toxic deaths. Overall 
response rates were similar 37%/ 40% (GC/MIP). However, there was a 
survival advantage to GC, log-rank p=0.0043 and median survival was GC 
10.0 months, MIP 6.5 months.  
These preliminary results suggest that GC is better tolerated and associated 
with longer survival than MIP.  Qol analyses and updated results will be 
presented. 
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CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER 
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The roles of adjuvant chemoradiotherapy and adjuvant chemotherapy in 
pancreatic cancer remain uncertain. The European Study Group for 
Pancreatic Cancer￿s (ESPAC) first study is the largest randomised adjuvant 
pancreatic trial designed to assess these roles and recruited 541 patients with 
resected pancreatic ductal adenocarcinoma. Previous studies have been 
somewhat under powered and often excluded patients with positive resection 
margins. ESPAC-1 included patients with positive resection margins as 
recognition of the natural behaviour of the disease and met the target of 
randomising 285 patients via a 2x2 factorial, with additional patients 
randomised into chemotherapy only (n=188) or chemoradiotherapy only 
(n=68) randomisation options. The preliminary results of ESPAC-1, with 314 
(58%) deaths and median follow-up of 10 months (inter-quartile range: 1-25) 
for alive patients, showed no evidence of a survival benefit for 
chemoradiation but some evidence of benefit for chemotherapy (Lancet 2001; 
358: 9293, 1576-1585). 
A meta-analysis of the interim data from ESPAC-1 with data from the 
Gastrointestinal Tumor Study Group (GITSG), the European Organization 
for Research and Treatment of Cancer (EORTC) and the Norwegian 
Pancreatic Cancer Trials Group has been carried out to assess world-wide 
evidence for chemoradiation and chemotherapy. ESPAC-1 dominates the 
analysis due to it￿s large size and results confirm no overall benefit for 
chemoradiation (risk reduction ￿4%, p=0.71) and a benefit for chemotherapy 
(risk reduction 35%, p<0.001).  
The last ESPAC-1 patient was randomised in April 2000 hence with a 
minimum follow-up of 2 years final results will be available April 2002. 
These will be combined with individual patient data from the EORTC and 
Norwegian groups to allow global investigation of important prognostic 
variables and confirm treatment effects within specific subgroups of patients 
with resectable pancreatic adenocarcinoma. 
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Between January 1993 and October 2001 457 patients with newly diagnosed 
histologically aggressive NHL and poor prognosis disease defined as age-
adjusted IPI score of high and high-intermediate risk were entered into this 
trial.  Histology included diffuse large B-cell lymphoma, grade 3 follicular 
lymphoma, anaplastic large cell lymphoma and peripheral T cell lymphomas.  
Lymphoblastic lymphomas and Burkitts lymphoma were excluded.   
Patients were randomised to receive standard CHOP therapy (6-8 cycles with 
at least 2 cycles beyond CR) (n=232) or CHOP x 3 followed by BEAM and 
ASCT (n=225) providing there had been an objective response to CHOP with 
no progression at any site, and the bone marrow was morphologically clear of 
lymphoma after 3 cycles of CHOP.  Consolidation radiotherapy was at the 
discretion of the individual centres. 
The median age was 48 years (range 16-65) with 278 males and 179 females. 
The primary endpoint was overall survival (OS) and with a median follow-up 
of 54 months there is no difference between the two arms (χ
2=0.15, p=0.7). 
The actuarial overall survival in the CHOP arm was 54% at 5 years and in the 
CHOP + BEAM arm was 50 % at 5 years. In the CHOP + BEAM arm only 
62% of the randomised patients proceeded to BEAM.  Reasons for failure to 
receive BEAM included: inadequate response to CHOP (40%), persisting 
marrow disease (10%), patient choice (27%), physician choice reflecting the 
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progression free survival (PFS) will be presented. 
This study shows that high dose therapy after only 3 cycles of CHOP is not of 
overall benefit in poor risk patients.  The lack of adequate response to the 
initial 3 cycles of CHOP in nearly 20% of patients indicates that future trials 
must address early intensification of therapy.    
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Introduction: Sentinel Node Biopsy (SNB) is a guided technique for 
determining axillary lymph node status of patients with breast cancer.  Whilst 
it is hoped that SNB will eliminate unnecessary surgery for two thirds of 
breast cancer patients who currently receive standard axillary treatment, 
either axillary clearance or axillary sampling, to date there has been no 
detailed evaluation of this new technique in the form of a large randomised 
trial.  One of the issues raised by the SNB technique is the management of 
the internal mammary nodes.  
The ALMANAC trial (Axillary Lymphatic Mapping Against Axillary Nodal 
Clearance) is a two staged, multi-centre trial comparing SNB with standard 
axillary treatment in the management of breast cancer.  The first stage, now 
completed, was an Audit stage where surgeons were evaluated on their ability 
to successfully perform the technique.  The second stage, which is currently 
ongoing, is comparing SNB with standard axillary treatment in terms of arm 
and axilla morbidity, health economics and quality of life.  The Audit stage 
data is presented here. 
Method: In the Audit stage, surgeons performed a sentinel node biopsy 
before going on to perform their standard axillary procedure, either axillary 
sampling or axillary clearance. The sentinel node was localised using a 
combined technique of a radioisotope (Technetium 99m) and blue dye 
(Patent blue V).  In accordance with the ALMANAC protocol the patient was 
either injected with the radioisotope the day before the operation (40MBq) or 
on the day of operation (20MBq).  This was followed by a static 
lymphoscintiscan at least three hours from the time of injection. The drainage 
site was recorded and the number of hot nodes noted. 
Results: In total 29 surgeons took part in the Audit stage and 803 patients 
were recruited. Eight patients did not receive a scan due to logistical 
problems.  Data was missing on a further 26 patients leaving 769 cases of 
analysable data.  There were 206 cases (27%) where no drainage site was 
reported on the scan and 563 cases (73%) where drainage was reported. 
Axillary drainage was reported in 537(70%) cases and internal mammary 
drainage in 63(8%).  Of the 63 patients, only 22(35%) had lymph nodes 
removed of which 2 ￿nodes￿ proved to be fatty tissue. Only 4 patients had 
internal mammary nodes that were pathologically positive and in 2 of the 
patients the axillary nodal status was negative. One patient sustained a 
pneumothorax and one patient suffered bleeding from the internal mammary 
artery. 
Conclusion:  Removing the internal mammary nodes remains a difficult 
routine procedure.  Due to the relatively small percentage of patients that 
have positive internal mammary nodes with negative axillary status (ie have a 
change in stage), we conclude that routine removal of internal mammary 
nodes will have a minimal effect on the mortality from breast cancer. 
CT6 
THE BIG LUNG TRIAL (BLT): DETERMINING THE VALUE OF 
CISPLATIN-BASED CHEMOTHERAPY FOR ALL PATIENTS WITH 
NON-SMALL CELL LUNG CANCER (NSCLC). PRELIMINARY 
RESULTS IN THE SUPPORTIVE CARE SETTING. 
*RJ Stephens
1, JM Brown
2, DJ Fairlamb
3, N Gower
4, L Maslove
5, R Milroy
6,
V Napp
2, MD Peake
7, RM Rudd
8, S Spiro
9,
*H Thorpe
2, D Waller
7 on behalf 
of all the participants. 
1MRC Clinical Trials Unit, London. 
2Northern & Yorkshire Clinical Trials & 
Research Unit, University of Leeds. 
3Deanesly Centre, New Cross Hospital, 
Wolverhampton. 
4CRC & UCL Cancer Trials Centre, London. 
5York Health 
Economics Consortium, University of York. 
6Stobhill NHS Trust, Glasgow. 
7Glenfield Hospital, Leicester. 
8Dept of Medical Oncology, St 
Bartholomew￿s Hospital, London. 
9Dept of Thoracic Medicine, The 
Middlesex Hospital, London. 
This large multicentre randomised trial investigated the role of short-term 
cisplatin-based chemotherapy for all patients with NSCLC. In addition to 
their primary treatment (surgery, radical radiotherapy or ￿best supportive 
care￿) patients were randomised to chemotherapy (CT) or no chemotherapy 
(NoCT). CT could be cisplatin/vindesine (CV), mitomycin/ifosfamide/ 
cisplatin (MIC), mitomycin/ vinblastine/ cisplatin (MVP) or 
vinorelbine/cisplatin (NP). Recruitment closed on 30 November 2001 with a 
total of 1394 patients. 
Preliminary results in the supportive care setting 
725 patients were randomised (364 CT, 361 NoCT). Pre-treatment 
characteristics: median age 65 years, 74% male, 53% squamous cell, 79% 
WHO PS 0-1. In the CT group: 65% received the prescribed 3 cycles of 
chemotherapy (48% with no delays or modification), 28% had grade 3/4 
toxicity, mainly haematological (12%), nausea/vomiting (4%) and 
neutropenic fever (2%), and there were 14 (4%) reported treatment-related 
deaths. There was a significant survival advantage to the CT group: HR 0.77 
(95%CI 0.66-0.91), p=0.0015. 
Quality of Life (QL) was assessed in a subgroup of 273 patients using patient 
completed diary cards and the EORTC QLQ-C30 & LC17. There was no 
evidence of a difference in the pre-defined primary QL endpoint (global 
health status/QL at 12 weeks) or in any of the secondary endpoints (physical 
functioning, emotional functioning, fatigue, pain and dyspnoea). Health 
service costs, estimated in a subgroup of 194 patients using retrospective 
resource use data collected from hospital records, showed no evidence of a 
significant offset between the cost of CT and the cost of symptom 
management. 
The preliminary results of this, the largest trial in this setting, confirm the 
previously reported overall survival benefit with cisplatin-based 
chemotherapy, as well as the improvement in median survival of 
approximately 8 weeks. In addition, the sub-studies suggest no evidence of a 
difference in QL or economic benefit. 
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Aim of the Study
The was to determine whether four cycles of chemotherapy given after 
surgery and before radiotherapy (RT) would improve the outcome for 
patients with M0-1 medulloblastoma compared with RT alone. 
Patients and Methods
Patients aged 3-16 inclusive were randomised to either chemotherapy 
(vincristine 1.5 mg/m
2 weekly for three weeks, etoposide 100mg/m
2 daily for 
3 days and carboplatin 500 mg/m
2 daily for 2 days alternating with 
cyclophosphamide 1.5 g/m
2) followed by craniospinal RT 35 Gy in 21 
fractions with a boost of 20 Gy in 12 fractions to the posterior fossa, or RT 
alone.  
Results
217 patients were randomised and 179 eligible for analysis (chemotherapy + 
RT: 90, RT alone: 89). Median age was 7.67 years. Median follow-up was 
4.71 years. For all eligible patients overall survival (OS) was 78.9% at 3 
years and 71.4% at 5 years. Event free survival (EFS) was 71.5% at 3 years 
and 66.7% at 5 years. A significant difference in EFS was demonstrated for 
chemotherapy + RT compared with RT alone. For chemotherapy + RT, EFS 
was 78.7% at 3 years and 73.4% at 5 years compared with 64.2% at 3 years 
and 60.0% at 5 years for RT alone (p=0.0419). There was no statistically 
significant difference in 3-year and 5-year OS between the two arms (82.1% 
and 76.1% for Chemotherapy + RT, compared with 75.8% and 66.5% for RT 
alone, p = 0.1662). For patients who had undergone a total resection EFS was 
significantly better with chemotherapy + RT than with RT alone (p=0.0346), 
but not for patients who had undergone a less than total resection (p=0.4835). 
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within 50 days compared with those taking more than 50 days to complete.  
Multivariate analysis identified extent of surgical resection (p=0.0398), use of 
chemotherapy (p=0.0228) and time to complete RT (0.0056) as having a 
significant impact on EFS.
Conclusions
This is the first multi-centre, randomised study to demonstrate an improved 
EFS for patients with medulloblastoma  treated with pre-RT chemotherapy 
compared with RT alone.  The importance of avoiding gaps in RT schedules 
has been confirmed.   
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Introduction:  Cancer networks have the potential to make a powerful 
contribution to cancer research through collaborative studies.  We conducted 
a feasibility study in the Northern and Yorkshire Region that attempted to 
recruit all eligible patients (pts.) into a randomised trial of adjuvant 
chemotherapy following radical local treatment for muscle invasive TCC of 
the bladder. 
Patients and Methods:  The protocol was approved by Northern and 
Yorkshire Multicentre Research Ethics Committee.  The target was to 
randomise 60 pts. within 2 years. Consenting pts. were registered at 
diagnosis. Following primary therapy (cystectectomy [CYST] or radical 
radiotherapy [RRT]), pts. were assessed for fitness to start 3 cycles of MVAC 
chemotherapy within 12 weeks. If suitable, they were given further 
information and randomised if they consented. 
Result: The trial was activated in 20 hospitals with enthusiastic support. 354 
pts. were registered. 21% were not suitable for radical primary therapy due to 
metastatic disease or co-morbidity. Of the remainder, 50% had CYST and 
50% had RRT. After CYST/RRT, 67% / 81% were medically unfit for 
chemotherapy. Of the 15% eligible for randomisation, 75% declined. The 
final number of patients randomised was 6. 
Conclusion: This study demonstrates that population-based cancer research 
within the NHS is feasible.  In the patient group studied there was a higher 
incidence of co-morbidity than expected and many pts. declined 
randomisation. This experience is relevant to the development of the new 
National Cancer Research Network.  The difficulty in recruitment in this area 
supports the recent decision by co-operative groups to collaborate in a 
international intergroup study to address the issue of adjuvant chemotherapy 
for bladder cancer. 
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